Dubai Telegraph - Pfizer Covid vaccine for under-fives effective with three doses

EUR -
AED 3.902662
AFN 71.721309
ALL 97.379693
AMD 411.736337
ANG 1.916033
AOA 969.546232
ARS 1060.127839
AUD 1.625131
AWG 1.914127
AZN 1.801069
BAM 1.95799
BBD 2.146602
BDT 127.04809
BGN 1.957961
BHD 0.40045
BIF 3079.178589
BMD 1.062518
BND 1.422859
BOB 7.372594
BRL 6.109269
BSD 1.063139
BTN 89.778648
BWP 14.463859
BYN 3.479155
BYR 20825.362437
BZD 2.142898
CAD 1.481204
CDF 3048.36535
CHF 0.93686
CLF 0.037964
CLP 1047.547807
CNY 7.684238
COP 4713.916414
CRC 544.034137
CUC 1.062518
CUP 28.15674
CVE 110.873467
CZK 25.383911
DJF 188.83088
DKK 7.460262
DOP 64.017024
DZD 141.785204
EGP 52.286219
ETB 129.094855
FJD 2.403428
GBP 0.833407
GEL 2.911181
GHS 17.441278
GMD 75.96944
GNF 9170.597089
GTQ 8.215576
GYD 222.406682
HKD 8.263897
HNL 26.62657
HTG 139.832992
HUF 410.833148
IDR 16783.435843
ILS 3.990905
INR 89.664885
IQD 1391.899224
IRR 44737.341364
ISK 147.509645
JMD 168.928957
JOD 0.753435
JPY 164.266469
KES 137.598404
KGS 91.590977
KHR 4308.512491
KMF 489.156922
KRW 1495.616936
KWD 0.326842
KYD 0.885933
KZT 527.584963
LAK 23332.906547
LBP 95201.656596
LKR 310.88237
LRD 196.937992
LSL 19.305457
LTL 3.137341
LVL 0.642707
LYD 5.169153
MAD 10.541246
MDL 19.030182
MGA 4930.08572
MKD 61.689003
MMK 3451.018615
MOP 8.517928
MRU 42.388737
MUR 50.055102
MVR 16.426769
MWK 1843.46991
MXN 21.859829
MYR 4.714381
MZN 67.921539
NAD 19.306154
NGN 1777.25314
NIO 39.074133
NOK 11.766909
NPR 143.645436
NZD 1.791815
OMR 0.409087
PAB 1.063139
PEN 4.025844
PGK 4.265746
PHP 62.428268
PKR 295.327037
PLN 4.352023
PYG 8306.291093
QAR 3.868364
RON 4.977046
RSD 116.988606
RUB 104.392478
RWF 1451.40026
SAR 3.992277
SBD 8.862205
SCR 14.442803
SDG 639.107629
SEK 11.579093
SGD 1.422059
SLE 24.21852
SOS 607.24094
SRD 37.43785
STD 21991.987562
SVC 9.302844
SZL 18.732581
THB 36.986341
TJS 11.300434
TMT 3.72944
TND 3.344276
TOP 2.488527
TRY 36.515562
TTD 7.224421
TWD 34.473942
TZS 2828.280754
UAH 44.030751
UGX 3906.553553
USD 1.062518
UYU 44.822246
UZS 13632.112684
VES 47.682447
VND 26934.843765
XAF 656.722488
XCD 2.871509
XDR 0.800934
XOF 646.010986
XPF 119.331742
YER 265.443696
ZAR 19.237269
ZMK 9563.943308
ZMW 28.943737
ZWL 342.130521
  • CMSC

    -0.1800

    24.54

    -0.73%

  • SCS

    0.0200

    13.67

    +0.15%

  • BCC

    -2.0100

    141.13

    -1.42%

  • RIO

    -1.4000

    61.2

    -2.29%

  • JRI

    -0.3000

    13.22

    -2.27%

  • RBGPF

    0.0300

    60.22

    +0.05%

  • BCE

    -0.1600

    27.69

    -0.58%

  • CMSD

    -0.2100

    24.75

    -0.85%

  • BTI

    0.0900

    35.24

    +0.26%

  • RYCEF

    -0.1700

    7.16

    -2.37%

  • AZN

    0.4000

    65.19

    +0.61%

  • GSK

    -0.8300

    35.52

    -2.34%

  • NGG

    -1.2400

    62.9

    -1.97%

  • RELX

    -1.2100

    46.59

    -2.6%

  • BP

    -0.7600

    28.16

    -2.7%

  • VOD

    -0.8500

    8.47

    -10.04%

Pfizer Covid vaccine for under-fives effective with three doses
Pfizer Covid vaccine for under-fives effective with three doses / Photo: JACK GUEZ - AFP

Pfizer Covid vaccine for under-fives effective with three doses

The Pfizer/BioNTech Covid vaccine is safe and effective for children aged six months to under five years when given in three doses, the companies said in a statement Monday.

Text size:

The announcement comes as the US Food and Drug Administration (FDA) is planning meetings in the coming weeks to weigh authorizing Covid vaccines among the youngest children, the only age group who are not yet eligible in most countries, a source of concern to many parents.

Pfizer/BioNTech evaluated three doses, given at three micrograms, in a clinical trial and found the vaccine evoked a strong immune response. Side effects were similar in the vaccine and placebo groups.

Vaccine efficacy was 80.3 percent, according to a preliminary estimate.

"We are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth of the dose strength for adults, was well tolerated and produced a strong immune response," said Pfizer CEO Albert Bourla in a statement.

"We look forward to soon completing our submissions to regulators globally with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory authorization," he added.

The FDA has tentatively scheduled three dates in June where experts will meet and likely decide whether to authorize the Pfizer Covid vaccine for under-fives and the Moderna vaccine for under-sixes, which is given as two shots of 25 micrograms.

The agency was originally set to evaluate the Pfizer vaccine given as two doses in February, but data showed it did not provoke a strong enough immune response in children aged two to four. The FDA then asked to see data for a third shot.

- Data welcomed -

According to the new data, 1,678 children received a third dose at least two months after the second dose, at a time when Omicron was the predominant variant.

An analysis of a subset of participants showed antibody levels were similar to 16- to 25-year-olds who were given the full strength vaccine at two doses.

No new adverse events were identified, and the majority of side effects were mild or moderate.

"Three doses of (Pfizer's) Covid vaccine appear to be very safe and highly effective in preventing not only severe disease, hospitalization, and death from Covid, but even symptomatic Covid at a time when Omicron was the dominant variant," Celine Gounder, editor-at-large for public health at Kaiser Health News told AFP.

"However, we know that protection against SARS-CoV-2 infection and milder symptomatic disease wanes over time," added Gounder, an infectious disease specialist and epidemiologist.

"Pfizer is reporting follow-up data only out to seven days after the third dose of vaccine. It's too early to say how the three-dose series would perform out to several months or a year."

Jeremy Faust, of Brigham and Women's Hospital Department of Emergency Medicine, told AFP: "My first impression is very positive. These numbers are exactly the kinds of signals we wanted to see."

"I wish the two-dose series had worked for Pfizer/BioNTech. It didn't. But the three-dose series appears to have given these very young children the protection we want them to have," the doctor added.

If and when both Pfizer's and Moderna's vaccines are authorized, US parents will have to consider whether they want their children to receive Moderna's two dose vaccine -- which will offer faster protection -- or Pfizer's three doses -- which will take longer to be effective but may ultimately be more protective.

Pfizer's announcement comes one week after US health authorities gave the green light for the company's Covid booster shots to be administered to children age five to 11.

Severe disease from Covid is very rare among under-fives but can occur, with 477 US deaths in this age group since the start of the pandemic, or about 0.1 percent of all deaths.

Children can also contract a rare post-viral condition called multisystem inflammatory syndrome in children (MIS-C), which has affected some 8,210 US children and killed 68.

Like adults, some children who get Covid may go on to develop long Covid, with new, ongoing or returning symptoms, including brain fog and fatigue.

Y.Amjad--DT